Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Herceptin Increases event-free survival in locally advanced HER2-postive breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.03.09
Views: 14297
Rating:

Dr Luca Gianni - Director of Medical Oncology, National Cancer Institute, Milan

Among patients with HER2-positive, locally advanced breast cancer, neoadjuvant treatment with Herceptin increased three-year, event-free survival to 70 percent compared with 53 percent among those receiving chemotherapy alone. The addition of trastuzumab (Herceptin) was well tolerated with acceptable cardiac safety. Researchers claim this phase III clinical trial establishes chemotherapy with one year of Herceptin as a standard treatment option in this patient population. Speaking at the 2008 San Antonio Breast Cancer Symposium.

Categories:

Breast SABCS 2008

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation